| Name | Title | Contact Details |
|---|
Immunicom, Inc. is a privately held medical technology company that develops subtractive therapies for cancer, autoimmune disorders, and inflammatory and renal diseases. Immunicom`s blood-filtering Immunopheresis technology has the potential to effectively treat a wide variety of cancer types and other terminal diseases with a safer side-effect profile than conventional treatments. Immunicom`s lead product, the LW-02 column, previously received FDA Breakthrough Device designation in 2018 for stage IV metastatic cancer, and European regulatory clearance (CE Mark certification) in 2021 for use in adults with advanced, refractory, triple negative breast cancer. Immunopheresis is being evaluated in several global oncology trials for multiple cancers. Immunicom is headquartered in San Diego, CA with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.
We are a team of inspired individuals, driven by love of science, commitment to collaboration, and relentless pursuit of excellence. Lumen`s technology allows it to create clever new high-value products in spirulina (Arthrospira platens), a type of blue-green algae.
At Cradle Genomics, our mission is to provide knowledge that helps every pregnancy.
Sapphire Energy believes the time is now to create new energy solutions that are environmental, scalable, and renewable. Sapphire is leading the new industrial category of Green Crude production with the potential to profoundly change America’s energy and petrochemical landscape for the better. With only sunlight and CO2, Sapphire Energy is turning algae into Green Crude that can be refined into the three most important liquid fuels we use today: gasoline, diesel and jet fuel. There is no need to make changes to our vehicles, pipelines, or distribution systems—as Green Crude offers a complete drop-in replacement solution.